What is Precigen's non-cash interest expense?

Precigen (PGEN) reported non-cash interest expense of $345K in Q1 2026.

What is the long-term trend for Precigen's non-cash interest expense?

Over 2 years (2021 to 2024), Precigen's non-cash interest expense has grown at a -100.0% compound annual growth rate (CAGR), from $11.74M to $0.

Precigen PGEN Non-cash interest expense

Non-cash interest expense at other companies

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$23.3M+1,634%

Operating income-$6.0M+73.5%

Net income-$7.9M+85.4%

EPS (diluted)-$0.02+88.9%

Balance sheet

See full

Cash & equivalents$7.5M+23.5%

Total debt$98.3M+1,714%

Total equity$20.2M+244%

Total assets$138.6M+7.6%

Cash flow

See full

Operating cash flow-$43.8M-168%

CapEx$258.0K-58.5%

Free cash flow-$44.1M-160%

Valuation

See full

Market cap$1.91B+213%

Enterprise value$2B+234%

P/S72×—

Profitability

See full

Gross margin83.6%—

Operating margin-2,890.9%—

Net margin-3,656%—

FCF margin-1,756.5%—

Returns & leverage

See full

Return on equity-843.6%-1,103pp

Debt / equity4.9×—

Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's non-cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Precigen's non-cash interest expense?: Precigen (PGEN) reported non-cash interest expense of $345K in Q1 2026.
What is the long-term trend for Precigen's non-cash interest expense?: Over 2 years (2021 to 2024), Precigen's non-cash interest expense has grown at a -100.0% compound annual growth rate (CAGR), from $11.74M to $0.